|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
|
US5652338A
(en)
|
1988-03-16 |
1997-07-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Neutrophil chemotactic factor
|
|
DE68920321T2
(de)
|
1988-05-02 |
1995-05-24 |
Us Health |
Verfahren zur herstellung eines menschlichen "neutrophil chemotactic factor"-polypeptids.
|
|
KR100197110B1
(ko)
|
1988-08-29 |
1999-06-15 |
로버트 란만 |
활성 사람 호중구 화학주성 인자 폴리펩티드의 제조방법
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5427098A
(en)
|
1988-12-22 |
1995-06-27 |
Biofield Corp. |
Noninvasive method for determining treatment based upon lesion cell proliferation measurements
|
|
GB8909218D0
(en)
|
1989-04-22 |
1989-06-07 |
Medical Res Council |
Improvements in or relating to enhancers
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
WO1996033735A1
(en)
|
1995-04-27 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
IE913192A1
(en)
|
1990-09-12 |
1992-02-25 |
Scripps Research Inst |
Active site of interleukin-8: polypeptide analogs and¹antibodies
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
|
US5776457A
(en)
|
1991-03-29 |
1998-07-07 |
Genentech, Inc. |
Antibodies to human PF4A receptor and compositions thereof
|
|
ATE194385T1
(de)
|
1991-03-29 |
2000-07-15 |
Genentech Inc |
Menschliche pf4a rezeptoren und ihre verwendung
|
|
US5840856A
(en)
|
1991-03-29 |
1998-11-24 |
Genentech, Inc. |
Antibodies to a human PF4 superfamily receptor
|
|
US5571702A
(en)
|
1991-03-29 |
1996-11-05 |
Genentech, Inc. |
Amplification method for detection of human PF4A receptors
|
|
US5919896A
(en)
|
1991-03-29 |
1999-07-06 |
Genentech, Inc. |
PF4A receptor
|
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
|
US6087475A
(en)
|
1991-12-19 |
2000-07-11 |
Genentech, Inc. |
PF4A receptor
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
US5508717A
(en)
|
1992-07-28 |
1996-04-16 |
Sony Corporation |
Computer pointing device with dynamic sensitivity
|
|
US6200558B1
(en)
|
1993-09-14 |
2001-03-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
|
|
JPH08509612A
(ja)
|
1993-04-26 |
1996-10-15 |
ジェンファーム インターナショナル インコーポレイテッド |
異種抗体を産生することができるトランスジェニック非ヒト動物
|
|
US6448379B1
(en)
|
1993-09-14 |
2002-09-10 |
Chiron Corporation |
IL8 inhibitors
|
|
US5707622A
(en)
|
1994-03-03 |
1998-01-13 |
Genentech, Inc. |
Methods for treating ulcerative colitis
|
|
US5874080A
(en)
|
1994-03-03 |
1999-02-23 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of asthma
|
|
AU2466095A
(en)
|
1994-04-28 |
1995-11-29 |
Music Vending, Inc. |
Music vending system
|
|
DE69535243T2
(de)
|
1994-07-13 |
2007-05-10 |
Chugai Seiyaku K.K. |
Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
|
|
US5707621A
(en)
|
1994-08-31 |
1998-01-13 |
Chugai Pharmaceutical Co., Ltd. |
Supression of nephritis-induced protein excretion by anti-IL-8
|
|
EP0806962A4
(en)
|
1995-01-23 |
2001-01-10 |
Univ California |
Methods for the treatment of acid aspiration-induced acute lung injury
|
|
WO1997039772A1
(fr)
|
1996-04-19 |
1997-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
|
|
US6497878B1
(en)
|
1996-04-23 |
2002-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
|
|
WO1997049426A1
(fr)
|
1996-06-26 |
1997-12-31 |
Chugai Seiyaku Kabushiki Kaisha |
Medicaments destines aux lesions pulmonaires aigues dues a des causes indirectes, contenant un anticorps anti-il-8 comme principe actif
|
|
AU3048797A
(en)
|
1996-10-22 |
1998-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Sepsis remedy comprising anti-il-8 antibody as active ingredient
|
|
US6870033B1
(en)
|
1997-02-21 |
2005-03-22 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
|
|
CN1068524C
(zh)
|
1997-06-23 |
2001-07-18 |
叶庆炜 |
一种治疗顽症牛皮癣的药物
|
|
WO1999037779A1
(en)
|
1998-01-22 |
1999-07-29 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US6177077B1
(en)
|
1999-02-24 |
2001-01-23 |
Edward L. Tobinick |
TNT inhibitors for the treatment of neurological disorders
|
|
US6419944B2
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of localized disorders
|
|
US6419934B1
(en)
|
1999-02-24 |
2002-07-16 |
Edward L. Tobinick |
TNF modulators for treating neurological disorders associated with viral infection
|
|
US6423321B2
(en)
|
1999-02-24 |
2002-07-23 |
Edward L. Tobinick |
Cytokine antagonists for the treatment of sensorineural hearing loss
|
|
US6015557A
(en)
|
1999-02-24 |
2000-01-18 |
Tobinick; Edward L. |
Tumor necrosis factor antagonists for the treatment of neurological disorders
|
|
IL129180A0
(en)
|
1999-03-25 |
2000-02-17 |
Technion Res & Dev Foundation |
Method and pharmaceutical composition for wound healing
|
|
PL354286A1
(en)
|
1999-08-23 |
2003-12-29 |
Dana-Farber Cancer Institutedana-Farber Cancer Institute |
Pd-1, a receptor for b7-4, and uses therefor
|
|
JP5004390B2
(ja)
|
1999-08-23 |
2012-08-22 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
新規ｂ７−４分子およびその用途
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
|
DE19952622A1
(de)
|
1999-11-02 |
2001-05-10 |
Bayer Ag |
Verfahren zur Herstellung von rekombinantem Interleukin-8 und Interleukin-8 Muteinen
|
|
US6680209B1
(en)
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
|
US6420346B1
(en)
|
2000-02-07 |
2002-07-16 |
Rappaport Family Institute For Research In The Medical Sciences |
Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
|
|
AR030753A1
(es)
|
2000-09-25 |
2003-09-03 |
Smithkline Beecham Corp |
Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
|
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
CA2436595C
(en)
|
2000-12-08 |
2011-11-08 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
|
US20030068319A1
(en)
|
2001-03-23 |
2003-04-10 |
Menashe Bar-Eli |
Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors
|
|
JP2005520854A
(ja)
|
2002-03-19 |
2005-07-14 |
アブジェニックス・インコーポレーテッド |
慢性閉塞性肺疾患（ｃｏｐｄ）を治療するための方法
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
NZ541050A
(en)
|
2002-12-16 |
2010-06-25 |
Genmab As |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20050142136A1
(en)
|
2003-10-23 |
2005-06-30 |
Lary Suva |
Anti-interleukin 8 therapy for tumor osteolysis
|
|
US20090145493A1
(en)
|
2004-11-23 |
2009-06-11 |
Pip Co., Ltd. |
Built-in wall water service box
|
|
MX2007013058A
(es)
|
2005-04-20 |
2008-02-22 |
Amgen Fremont Inc |
Anticuerpos monoclonales de alta afinidad completamente humanos para interleucina-8 y epitopes para dichos anticuerpos.
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
US20110105724A1
(en)
|
2007-08-16 |
2011-05-05 |
Stephanie Jane Clegg |
Novel compounds
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
CA2840018C
(en)
|
2011-07-24 |
2019-07-16 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
WO2013166099A1
(en)
|
2012-05-01 |
2013-11-07 |
Glaxosmithkline Llc |
Novel antibodies
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
TWI612059B
(zh)
|
2013-03-15 |
2018-01-21 |
美國禮來大藥廠 |
泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
|
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
|
EP3194440A1
(en)
*
|
2014-09-15 |
2017-07-26 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
|
|
DK3303396T5
(da)
*
|
2015-05-29 |
2024-10-07 |
Bristol Myers Squibb Co |
Antistoffer mod ox40 og anvendelser deraf
|
|
EP3423494A1
(en)
*
|
2016-03-04 |
2019-01-09 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
ES2954139T3
(es)
*
|
2016-06-02 |
2023-11-20 |
Bristol Myers Squibb Co |
Bloqueo de PD-1 con nivolumab en el linfoma de Hodgkin refractario
|
|
SG10202101062YA
(en)
*
|
2016-06-02 |
2021-03-30 |
Bristol Myers Squibb Co |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
|
JP2019517512A
(ja)
*
|
2016-06-03 |
2019-06-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用
|
|
CA3084370A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|